FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117216710> ?p ?o ?g. }

• W2117216710 endingPage "1863" @default.
• W2117216710 startingPage "1858" @default.
• W2117216710 abstract "BackgroundTo offer minimized risk-adapted adjuvant treatment on a community and nationwide basis for patients with clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT). The aim was to reduce the risk of relapse and thereby reducing the need of later salvage chemotherapy while maintaining a high cure rate.Patients and methodsFrom July 1995 to January 1998, a total of 232 Swedish and Norwegian patients were treated for CS1 NSGCT. All were eligible for inclusion into one of two community-based multicenter Swedish and Norwegian Testicular Cancer Project (SWENOTECA) III studies. One study was a prospective randomized study for patients without vascular invasion in the testicular tumor (VASC-), evaluating the effect of one adjuvant course of cisplatin, vinblastine and bleomycin (CVB) compared with surveillance. The second study was a prospective study evaluating the effect of two adjuvant courses of CVB for VASC+ patients.ResultsDue to slow accrual and emerging data on toxicity of CVB, the studies were prematurely closed for inclusion in 1998. Of the 232 CS1 patients treated during the study period, only 97 were included in the studies. As all remaining patients were managed according to the SWENOTECA III protocol, although not randomized, the data were pooled. At a median follow-up of 10.1 years, there have been 24 relapses. While one course of CVB to VASC- patients had limited effect on the relapse rate, two courses of adjuvant CVB reduced the relapse rate among VASC+ patients by >90%. Toxicity was high in patients administered adjuvant CVB as 24% of patients experienced grade 3 or 4 obstipation/ileus and 23% grade 3 or 4 infection.ConclusionsThere was no statistical difference in relapse rate between one course of adjuvant CVB and surveillance for VASC- NSGCT patients. Two courses of adjuvant CVB for VASC+ NSGCT patients reduced the relapse rate with >90% in comparison to the surveillance group. Toxicity was unacceptably high for all patients receiving CVB. Adjuvant CVB chemotherapy has no place in the treatment of CS1 NSGCT." @default.
• W2117216710 created "2016-06-24" @default.
• W2117216710 creator A5005553315 @default.
• W2117216710 creator A5031524511 @default.
• W2117216710 creator A5049243129 @default.
• W2117216710 creator A5050258103 @default.
• W2117216710 creator A5067619404 @default.
• W2117216710 creator A5075273410 @default.
• W2117216710 creator A5081738251 @default.
• W2117216710 date "2010-09-01" @default.
• W2117216710 modified "2023-10-16" @default.
• W2117216710 title "Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study" @default.
• W2117216710 cites W118559235 @default.
• W2117216710 cites W1866911875 @default.
• W2117216710 cites W1964944340 @default.
• W2117216710 cites W1965292019 @default.
• W2117216710 cites W1986538990 @default.
• W2117216710 cites W1989958216 @default.
• W2117216710 cites W1996057872 @default.
• W2117216710 cites W2006141228 @default.
• W2117216710 cites W2019369417 @default.
• W2117216710 cites W2053800335 @default.
• W2117216710 cites W2065241538 @default.
• W2117216710 cites W2080839610 @default.
• W2117216710 cites W2106614331 @default.
• W2117216710 cites W2108522817 @default.
• W2117216710 cites W2120321741 @default.
• W2117216710 cites W2124903087 @default.
• W2117216710 cites W2136033403 @default.
• W2117216710 cites W2140462124 @default.
• W2117216710 cites W2156136418 @default.
• W2117216710 cites W2158801184 @default.
• W2117216710 cites W2166066062 @default.
• W2117216710 cites W2170186442 @default.
• W2117216710 cites W2220613250 @default.
• W2117216710 cites W2259767564 @default.
• W2117216710 cites W2267995930 @default.
• W2117216710 cites W2282394251 @default.
• W2117216710 cites W4232182820 @default.
• W2117216710 cites W4293241248 @default.
• W2117216710 cites W4362231427 @default.
• W2117216710 cites W4375835367 @default.
• W2117216710 doi "https://doi.org/10.1093/annonc/mdq026" @default.
• W2117216710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20142410" @default.
• W2117216710 hasPublicationYear "2010" @default.
• W2117216710 type Work @default.
• W2117216710 sameAs 2117216710 @default.
• W2117216710 citedByCount "40" @default.
• W2117216710 countsByYear W21172167102012 @default.
• W2117216710 countsByYear W21172167102013 @default.
• W2117216710 countsByYear W21172167102014 @default.
• W2117216710 countsByYear W21172167102015 @default.
• W2117216710 countsByYear W21172167102016 @default.
• W2117216710 countsByYear W21172167102017 @default.
• W2117216710 countsByYear W21172167102018 @default.
• W2117216710 countsByYear W21172167102019 @default.
• W2117216710 countsByYear W21172167102021 @default.
• W2117216710 countsByYear W21172167102022 @default.
• W2117216710 countsByYear W21172167102023 @default.
• W2117216710 crossrefType "journal-article" @default.
• W2117216710 hasAuthorship W2117216710A5005553315 @default.
• W2117216710 hasAuthorship W2117216710A5031524511 @default.
• W2117216710 hasAuthorship W2117216710A5049243129 @default.
• W2117216710 hasAuthorship W2117216710A5050258103 @default.
• W2117216710 hasAuthorship W2117216710A5067619404 @default.
• W2117216710 hasAuthorship W2117216710A5075273410 @default.
• W2117216710 hasAuthorship W2117216710A5081738251 @default.
• W2117216710 hasBestOaLocation W21172167101 @default.
• W2117216710 hasConcept C126322002 @default.
• W2117216710 hasConcept C141071460 @default.
• W2117216710 hasConcept C143998085 @default.
• W2117216710 hasConcept C146357865 @default.
• W2117216710 hasConcept C151730666 @default.
• W2117216710 hasConcept C2776212926 @default.
• W2117216710 hasConcept C2776694085 @default.
• W2117216710 hasConcept C2776938808 @default.
• W2117216710 hasConcept C2777132456 @default.
• W2117216710 hasConcept C2777863537 @default.
• W2117216710 hasConcept C71924100 @default.
• W2117216710 hasConcept C86803240 @default.
• W2117216710 hasConceptScore W2117216710C126322002 @default.
• W2117216710 hasConceptScore W2117216710C141071460 @default.
• W2117216710 hasConceptScore W2117216710C143998085 @default.
• W2117216710 hasConceptScore W2117216710C146357865 @default.
• W2117216710 hasConceptScore W2117216710C151730666 @default.
• W2117216710 hasConceptScore W2117216710C2776212926 @default.
• W2117216710 hasConceptScore W2117216710C2776694085 @default.
• W2117216710 hasConceptScore W2117216710C2776938808 @default.
• W2117216710 hasConceptScore W2117216710C2777132456 @default.
• W2117216710 hasConceptScore W2117216710C2777863537 @default.
• W2117216710 hasConceptScore W2117216710C71924100 @default.
• W2117216710 hasConceptScore W2117216710C86803240 @default.
• W2117216710 hasIssue "9" @default.
• W2117216710 hasLocation W21172167101 @default.
• W2117216710 hasLocation W21172167102 @default.
• W2117216710 hasOpenAccess W2117216710 @default.
• W2117216710 hasPrimaryLocation W21172167101 @default.
• W2117216710 hasRelatedWork W1902616231 @default.

• next